New Ownership Expands MK&A’s Patient Engagement and Advocacy Expertise
I am pleased to announce the acquisition of MK&A by Cláudia Hirawat, a long-time friend, former client, and colleague. This strategic change strengthens MK&A’s ability to support our clients in ensuring that patients and their advocates are central to shaping health care. Cláudia’s commitment to patients, consumers, and health care professionals has been demonstrated repeatedly, first as president of pioneering biotech company PTC Therapeutics, and later as a volunteer for EURORDIS and other advocacy organizations. She has also contributed to our firm’s success across three years’ service on our board of advisors. Cláudia understands that advocacy and MK&A make a difference.
Since 1995, MK&A has enabled our clients to engage productively with multidisciplinary stakeholders and incorporate patients’ knowledge and preferences into all areas of a company. Among the myriad accomplishments of which we are most proud has been our ability to conceive and deliver innovative advocacy relations programs for hundreds of different diseases and conditions. We have also boosted corporate reputations, navigated the complexities of the orphan drug environment, and delivered innovative pre-approval drug access programs. We will build on these accomplishments by setting new standards of excellence, expanding our services, and helping define effective models of collaboration in global health care.
Cláudia and I are especially pleased that Ellen Coleman, MSSA, MPH is now our president and chief executive officer. Ellen has been with MK&A for eight years, and her expertise and dedication will be paramount as we advance the growth of the firm. I am invigorated by this new chapter of the MK&A story and will serve as chief strategic officer, partnering with Cláudia and Ellen to define and execute an enhanced vision for our firm. Our team in the US and Europe remains in place, continuing to deliver excellent work, as always.
We look forward to continuing to set the standard of excellence in patient engagement and advocacy relations, just as we remain grateful to all of our partners – companies, advocacy organizations, and many others – for their contributions to helping people live healthier lives.
Please join me in welcoming Cláudia Hirawat to MK&A and congratulating Ellen Coleman on her promotion to leading our firm.
Mark Krueger, MPH
Chief Strategic Officer
Back to Full Blog List